Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PET Assessment of Eszopiclone and Zolpidem CNS Effects
NCT00781482Phase 4Withdrawn
- Sponsor
- Kettering Health
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of eszopiclone in Insomnia, sponsored by Kettering Health. Primary endpoint: GABA receptor binding measured by PET imaging. Status: withdrawn.
02
Drugs
eszopiclone
03
Conditions
Insomnia
Beyond the preview
Go deeper on NCT00781482.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00781482.